Science Research Studies – Why Tesamorelin and Sermorelin Are Restricted Medicinal Products and Cannot Be Sold to the UK Public
Tesamorelin and sermorelin continue to appear on some UK peptide websites, frequently labelled “research use only.” However, direct written correspondence received by BioPlex Peptides from the Medicines and Healthcare products Regulatory Agency confirms that these substances are treated as medicinal products and cannot lawfully be offered through unrestricted public retail sale.
This is not simply a matter of changing a disclaimer, removing a dosage statement or placing “not for human consumption” on the product page. When a substance is classified as a medicine, the rules governing its authorisation, advertising, sale and supply apply.
BioPlex removed tesamorelin and sermorelin from public sale after receiving this regulatory confirmation. UK sellers continuing to offer these restricted products directly to ordinary customers should examine their position urgently.
What Has the MHRA Confirmed?
BioPlex contacted the MHRA directly to clarify the UK regulatory position concerning tesamorelin and sermorelin.
The written response received by BioPlex confirmed that these products fall within medicines regulation and cannot be placed on unrestricted public sale as ordinary research peptides. Offering them through a standard online retail checkout does not become lawful merely because the seller describes them as laboratory products.
The important points are:
-
Tesamorelin and sermorelin are treated as medicinal products.
-
They are not ordinary unrestricted consumer products.
-
They cannot be advertised and sold to the general public without the required medicines authorisation.
-
A “research use only” label does not override their regulatory classification.
-
Supplying them as products intended or presented for human use is illegal.
-
Ordinary public retail access must be removed.
This regulatory position concerns the way these substances are classified, presented, advertised and supplied in the UK.
Why Are Tesamorelin and Sermorelin Classed as Medicines?
Tesamorelin and sermorelin are biologically active growth hormone-releasing hormone analogues. Their pharmacological purpose involves stimulating growth hormone release and modifying physiological function.
Under the Human Medicines Regulations 2012, a product may be classified as a medicinal product when it is:
-
Presented as preventing or treating disease.
-
Used or administered to restore, correct or modify a physiological function.
-
Pharmacologically, immunologically or metabolically active.
-
Presented to the public in a way that implies medical or human use.
A seller does not determine a product’s legal classification simply by choosing a different description. The MHRA can consider the substance itself, its known pharmacological action and the complete way in which it is offered to customers.
“Research Use Only” Is Not a Legal Loophole
Some sellers appear to believe that adding “research use only” or “not for human consumption” automatically takes a product outside medicines legislation.
That is incorrect.
The MHRA can examine the complete presentation of a product, including:
-
Product names and descriptions.
-
Claimed effects or benefits.
-
Packaging and vial labels.
-
Website imagery.
-
Dosage or reconstitution information.
-
Customer reviews.
-
Social-media posts.
-
Frequently asked questions.
-
Suggested combinations or “stacks.”
-
The type of customer able to purchase the product.
A research disclaimer cannot be used to disguise a product that is being advertised, understood or supplied as a medicine.
If a website allows any member of the public to buy tesamorelin or sermorelin through a normal checkout—particularly while displaying claims about fat reduction, growth hormone, recovery, anti-ageing, body composition or personal results—the wider presentation may demonstrate medicinal promotion and public supply.
The disclaimer does not erase that evidence.
Why Public Sale Is Different from Legitimate Research Supply
“Not available for public sale” does not necessarily mean a substance can never exist inside a legitimate scientific or pharmaceutical research environment.
Authorised universities, pharmaceutical developers, licensed laboratories and properly controlled clinical-research organisations may obtain regulated materials through specialist supply arrangements. These environments involve institutional checks, documented research purposes, controlled procurement and applicable regulatory authorisations.
That is fundamentally different from:
-
Listing a vial on a public peptide website.
-
Allowing unrestricted consumer checkout.
-
Selling through WhatsApp, Telegram or social media.
-
Advertising personal physical effects.
-
Providing human-use directions.
-
Accepting customer reviews describing administration.
-
Promoting combinations intended to alter human physiology.
Calling unrestricted retail customers “researchers” does not automatically create a legitimate institutional research arrangement.
Tesamorelin and Medicinal Presentation
Tesamorelin is a modified growth hormone-releasing factor analogue with recognised pharmacological activity. Outside the UK, an authorised tesamorelin medicine has been used for a specific medical indication under prescription controls.
That foreign authorisation does not permit a UK peptide retailer to sell tesamorelin directly to the public. A medicine authorised in another country is not automatically authorised for public retail sale in the UK.
Tesamorelin is also frequently promoted online using claims relating to abdominal fat, metabolism, growth hormone or body composition. These are not neutral laboratory descriptions. They can contribute directly to the presentation of the product as a medicine.
Selling the same substance with a “research use only” label does not cancel the nature of those claims.
Sermorelin and Medicinal Presentation
Sermorelin is a synthetic growth hormone-releasing hormone fragment with pharmacological activity affecting the human endocrine system.
It has a history of medicinal and prescription-controlled use. Marketing it for growth hormone stimulation, anti-ageing, recovery, sleep, muscle development, fat reduction or hormone optimisation presents it as a product intended to modify human physiological function.
Sermorelin cannot be converted into an unrestricted retail research product simply by removing obvious medical wording while continuing to sell it directly to public customers.
The substance, its function, the surrounding information and the method of supply must all be considered.
Testing Does Not Make Restricted Public Sale Legal
A certificate of analysis can provide useful information about a tested sample. Depending on the analytical method, it may help establish identity, purity, molecular mass or the presence of specified substances.
However, independent testing does not:
-
Grant MHRA approval.
-
Provide a UK marketing authorisation.
-
Change a medicine into an unrestricted research product.
-
Authorise public medicinal advertising.
-
Make direct-to-consumer supply legal.
-
Prove suitability for human use.
A seller cannot rely on a purity result or certificate of analysis as permission to sell a restricted medicinal product to the public.
Testing supports transparency. It does not replace regulatory authorisation.
What Should UK Peptide Sellers Do?
Any UK seller publicly listing tesamorelin or sermorelin should obtain direct regulatory advice and review the products immediately.
Removing dosage instructions while leaving the product available may not be enough. Changing the wording to “laboratory research only” may not be enough. Hiding human-use claims in blogs, customer reviews or social-media groups may not be enough.
Where the MHRA has classified a substance as a medicinal product, the seller must comply with the legal requirements governing medicines. Continuing ordinary public retail supply without the necessary authorisation may constitute the illegal sale or supply of an unauthorised medicine.
Sellers should not assume that competitors continuing to list a product proves that it is legal. A product remaining visible online is not evidence of MHRA approval.
Why BioPlex Removed Both Products
BioPlex Peptides sought clarification directly from the MHRA and acted on the written response received.
Tesamorelin and sermorelin were removed from public sale because maintaining unrestricted retail listings would not be consistent with the regulatory position communicated to BioPlex.
This decision reflects a straightforward principle: when the UK medicines regulator provides direct guidance about a product, a responsible supplier should act on it.
BioPlex will not knowingly continue selling a product to the public after being informed that it is treated as a restricted medicinal product. Commercial pressure and competitor activity do not take priority over regulatory responsibility.
A Warning to UK Customers
Customers should be cautious when a seller continues offering tesamorelin or sermorelin as though they were ordinary, unrestricted research products.
Ask the seller:
-
Has it contacted the MHRA about these specific products?
-
Can it provide written regulatory confirmation permitting public sale?
-
Does it hold the necessary medicines authorisation?
-
Why is the product available through unrestricted checkout?
-
Are its blogs, reviews or social-media posts describing human effects?
-
Is it incorrectly presenting laboratory testing as regulatory approval?
A professional-looking website, company registration or certificate of analysis does not prove that every product listed is lawful for public sale.
Final Conclusion
Direct correspondence received by BioPlex Peptides from the MHRA confirms that tesamorelin and sermorelin are treated as medicinal products and cannot lawfully remain available through unrestricted public retail sale.
These are not ordinary consumer research products. Their pharmacological activity, established medicinal context and ability to modify physiological function place them within medicines regulation.
Writing “research use only” on a vial does not provide a loophole. Independent testing does not provide authorisation. Removing dosage information does not necessarily make continued public sale lawful.
BioPlex removed tesamorelin and sermorelin after receiving the MHRA’s confirmation. Sellers continuing to offer either product to the general public should not assume that a disclaimer protects them from UK medicines law.
Continue Exploring...
Are Peptides Legal in the UK?
Read about MHRA rules, research use and BioPlex compliance ⟶
MHRA Compliance
View BioPlex Peptides MHRA compliance laws and research policies ⟶
Independent Peptide Testing
View BioPlex Peptides independent testing certificates and results ⟶
MHRA Product Classification
Read how the MHRA determines whether a product is a medicine ⟶
MHRA Advertising Rules
Read the official MHRA guidance for advertising medicines in the UK ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
